As interferon gamma (IFNγ) is known to inhibit Th2 cytokine production, the failure of a large clinical trial treating IPF patients with IFNγ provides doubt about whether Th2 responses are inherently disadvantageous to IPF (45). This evidence concerns the gene IFNG and idiopathic pulmonary fibrosis.